realtime ebv assay (Abbott Laboratories)
90
Structured Review
Abbott Laboratories
realtime ebv assay
Realtime Ebv Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/realtime+ebv+assay/realtime+ebv+assay/pm40578123-25-17-17
Average 90 stars, based on 1 article reviews
Realtime Ebv Assay, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/realtime+ebv+assay/realtime+ebv+assay/pm40578123-25-17-17
Average 90 stars, based on 1 article reviews
realtime ebv assay - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Polymerase Chain Reaction:Article Title: Multi-site performance evaluation of the Alinity m Molecular assay for quantifying Epstein-Barr virus DNA in plasma samples. Article Snippet: .. The Article Title: Evaluation of two automated real-time PCR-based quantification methods for whole blood Epstein-Barr viral load. Article Snippet: Quantification of EBV DNA is important in transplantation settings for the diagnosis of post-transplantation.. We evaluated the performance of the AltoStar® EBV PCR Kit 1.5 on whole blood specimens: limit of detection, linearity, accuracy, and precision were determined using the WHO NIBSC 09/260 international standard.. Results of 69 clinical samples were compared between the AltoStar® EBV PCR Kit 1.5 (altona Diagnostics) and the RealTime EBV assay (Abbott). Article Title: The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Article Snippet: Jutta Preiksaitis1 | Upton Allen2 | Catherine M. Bollard3 | Vikas R. Dharnidharka4 | Daniel E. Dulek5 | Michael Green6 | Olivia M. Martinez7 | Diana M. Metes8 | Marian G. Michaels6 | Françoise Smets9 | Richard E. Chinnock10 | Patrizia Comoli11 | Lara DanzigerIsakov12 | Anne I. Dipchand13 | Carlos O. Esquivel14 | Judith A. Ferry15 | Thomas G. Gross16 | Robert J. Hayashi17 | Britta Höcker18 | Arnaud G. L’Huillier19 | Stephen D. Marks20,21 | George Vincent Mazariegos22 | James Squires23 | Steven H. Swerdlow24 | Ralf U. Trappe25,26 | Gary Visner27 | Steven A. Webber28 | James D. Wilkinson28 | Brtitta MaeckerKolhoff29 Article Title: The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Article Snippet: 6 Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS).. It is likely to play a 7 causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular 8 mimicry, autoantigenic presentation or immune dysregulation.. Alternatively, evidence supports a 9 direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within 10 the central nervous system or the periphery. Article Title: Analytical and clinical evaluation of the cobas Epstein-Barr virus test at a tertiary care cancer hospital. Article Snippet: Background: Epstein–Barr Virus (EBV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically monitored using quantitative molecular assays.. The Cobas EBV test (Roche Molecular, Pleasanton, CA) has recently been FDA-cleared for the monitoring of EBV viral loads in plasma samples of transplant patients.. In this study, we compared the viral loads obtained by a laboratory-developed test (EBV LDT) using Altona Analyte specific reagents (ASR) to those obtained on the Cobas EBV test. Comparison:Article Title: The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Article Snippet: Jutta Preiksaitis1 | Upton Allen2 | Catherine M. Bollard3 | Vikas R. Dharnidharka4 | Daniel E. Dulek5 | Michael Green6 | Olivia M. Martinez7 | Diana M. Metes8 | Marian G. Michaels6 | Françoise Smets9 | Richard E. Chinnock10 | Patrizia Comoli11 | Lara DanzigerIsakov12 | Anne I. Dipchand13 | Carlos O. Esquivel14 | Judith A. Ferry15 | Thomas G. Gross16 | Robert J. Hayashi17 | Britta Höcker18 | Arnaud G. L’Huillier19 | Stephen D. Marks20,21 | George Vincent Mazariegos22 | James Squires23 | Steven H. Swerdlow24 | Ralf U. Trappe25,26 | Gary Visner27 | Steven A. Webber28 | James D. Wilkinson28 | Brtitta MaeckerKolhoff29 Article Title: The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Article Snippet: 6 Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS).. It is likely to play a 7 causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular 8 mimicry, autoantigenic presentation or immune dysregulation.. Alternatively, evidence supports a 9 direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within 10 the central nervous system or the periphery. Virus:Article Title: The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Article Snippet: Jutta Preiksaitis1 | Upton Allen2 | Catherine M. Bollard3 | Vikas R. Dharnidharka4 | Daniel E. Dulek5 | Michael Green6 | Olivia M. Martinez7 | Diana M. Metes8 | Marian G. Michaels6 | Françoise Smets9 | Richard E. Chinnock10 | Patrizia Comoli11 | Lara DanzigerIsakov12 | Anne I. Dipchand13 | Carlos O. Esquivel14 | Judith A. Ferry15 | Thomas G. Gross16 | Robert J. Hayashi17 | Britta Höcker18 | Arnaud G. L’Huillier19 | Stephen D. Marks20,21 | George Vincent Mazariegos22 | James Squires23 | Steven H. Swerdlow24 | Ralf U. Trappe25,26 | Gary Visner27 | Steven A. Webber28 | James D. Wilkinson28 | Brtitta MaeckerKolhoff29 Article Title: The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Article Snippet: 6 Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS).. It is likely to play a 7 causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular 8 mimicry, autoantigenic presentation or immune dysregulation.. Alternatively, evidence supports a 9 direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within 10 the central nervous system or the periphery. Clinical Proteomics:Article Title: The IPTA Nashville Consensus Conference on Post-Transplant lymphoproliferative disorders after solid organ transplantation in children: III - Consensus guidelines for Epstein-Barr virus load and other biomarker monitoring. Article Snippet: Jutta Preiksaitis1 | Upton Allen2 | Catherine M. Bollard3 | Vikas R. Dharnidharka4 | Daniel E. Dulek5 | Michael Green6 | Olivia M. Martinez7 | Diana M. Metes8 | Marian G. Michaels6 | Françoise Smets9 | Richard E. Chinnock10 | Patrizia Comoli11 | Lara DanzigerIsakov12 | Anne I. Dipchand13 | Carlos O. Esquivel14 | Judith A. Ferry15 | Thomas G. Gross16 | Robert J. Hayashi17 | Britta Höcker18 | Arnaud G. L’Huillier19 | Stephen D. Marks20,21 | George Vincent Mazariegos22 | James Squires23 | Steven H. Swerdlow24 | Ralf U. Trappe25,26 | Gary Visner27 | Steven A. Webber28 | James D. Wilkinson28 | Brtitta MaeckerKolhoff29 Article Title: The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis. Article Snippet: 6 Epstein-Barr virus (EBV) is strongly associated with multiple sclerosis (MS).. It is likely to play a 7 causal role in the pathogenesis of MS, possibly via triggering autoimmunity through molecular 8 mimicry, autoantigenic presentation or immune dysregulation.. Alternatively, evidence supports a 9 direct role for EBV in driving MS disease activity via latent-lytic infection cycling either within 10 the central nervous system or the periphery. |